Rivaroxaban: FDA and others [Design Issues]

posted by Tricky TAB – Bangladesh, 2022-07-05 08:42 (652 d 09:28 ago) – Posting: # 23105
Views: 1,844

❝ It depends on the ‘target’ agency.

Thanks a lot, Helmut!
For taking the time to help me out!

Wanted to perform BE for ASEAN Regions!
2x2x2 would matter anyway for those countries with same sample size as suggested in FDA guideline?

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
 Admin contact
22,985 posts in 4,823 threads, 1,653 registered users;
45 visitors (0 registered, 45 guests [including 8 identified bots]).
Forum time: 18:10 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz